No Data
No Data
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
10-Q: Quarterly report
Express News | NKGen Biotech Shares Are Trading Higher After the Company Announced Early Interim Data From the Phase 1 Cohort and the Dosing of the First Phase 2 Patient in the Phase 1/2a Clinical Trial of Troculeucel
Express News | NKGen Biotech Inc - No Drug-Related Adverse Reactions in Phase 1 Cohort After 3 Months
Express News | NKGen Biotech Inc - Two Phase 1 Patients Show Improved Cognitive Scores After 3 Months
Express News | NKGen Biotech’s Positive Phase 1 Clinical Data in Moderate Alzheimer’s Disease Advances Troculeucel Into Phase 2 With First Patient Dosed in Phase 1/2a Trial
No Data
No Data